Targets › MEN1
7 programs from 7 companies in 34 trials: 24 Phase 1, 5 Phase 2, 5 Phase 3; Oncology, Metabolic and endocrine; next expected readout Dec 2026.
Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. (UniProt, O00255)
Open in Phaseline: the race on MEN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kura Oncology | Ziftomenib (KO-539) Menin inhibitor | MEN1 | Phase 3 | Acute Myeloid Leukemia (AML); AML; Advanced Malignant Neoplasm; Gastrointestinal Stromal Tumor (GIST) … | Dec 2026 |
| Syndax Pharmaceuticals | revumenib Menin/Histone-lysine N-methyltransferase MLL inhibitor; Menin inhibitor | MEN1, KMT2A | Phase 3 | Acute Myeloid Leukemias; Acute Myeloid Leukemia; Acute Myeloid Leukemia, Adult; Recurrent Acute Leukemia of Ambiguous Lineage … | Feb 2027 |
| Johnson & Johnson (Janssen) | Bleximenib Menin inhibitor | MEN1 | Phase 3 | Leukemia, Myeloid, Acute; Acute Leukemia; Acute Myeloid Leukemia | Jun 2027 |
| M.D. Anderson Cancer Center | Revumenib Sesquifumarate (SNDX-5613) Menin/Histone-lysine N-methyltransferase MLL inhibitor | MEN1, KMT2A | Phase 2 | Leukemia; Acute Myeloid Leukemia | Dec 2026 |
| Biomea Fusion | icovamenib 100 mg Menin inhibitor | MEN1 | Phase 2 | Type 2 Diabetes | Mar 2027 |
| Uma Borate | Ziftomenib Menin inhibitor | MEN1 | Phase 2 | Acute Myeloid Leukemia | Dec 2027 |
| Sumitomo Pharma America | Enzomenib (DSP-5336) Menin inhibitor | MEN1 | Phase 1 | Leukemia, Myeloid, Acute | Jun 2027 |
Acute Myeloid Leukemia (12) Leukemia, Myeloid, Acute (3) Type 2 Diabetes (2) Acute Myeloid Leukemias (2) Acute Leukemia (2) Leukemia (2) Acute Myeloid Leukemia (AML) (1) AML (1) Advanced Malignant Neoplasm (1) Gastrointestinal Stromal Tumor (GIST) (1) KMT2A-rearranged (1) Refractory Acute Leukemia (1)
small molecule (5), mixed (2)
Biomea Fusion (1) Kura Oncology (1) Syndax Pharmaceuticals (1) M.D. Anderson Cancer Center (1) Johnson & Johnson (Janssen) (1) Sumitomo Pharma America (1) Uma Borate (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.